Description: Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of ABSK091 and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations, as well as a licensing agreement with Sperogenix (Shanghai) MedTech Co., Ltd. to develop and commercialize ABSK021 for indications in non-oncology neurological rare diseases. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Home Page: www.abbisko.com
Building 3
Shanghai,
China
Phone:
86 21 6891 2098
Officers
| Name | Title |
|---|---|
| Dr. Yao-Chang Xu | Founder, Chairman & CEO |
| Dr. Hongping Yu | Co-Founder, Sr. VP of Chemistry & Exec. Director |
| Dr. Zhui Chen | Co-Founder, Sr. VP of Biology & Exec. Director |
| Dr. Zidong Zhang | Chief Financial Officer |
| Ms. Huimin Tian | Head of Operations & Joint Company Sec. |
| Mr. Yongyi Li | Gen. Counsel |
| Ms. Jia Feng | Head of Human Resource |
| Dr. Kewei Xie | Chief Bus. Officer |
| Dr. Zhen Zhang | VP and Head of Chemistry, Manufacturing & Controls |
| Dr. Jing Ji | Chief Medical Officer |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8507 |
| Price-to-Sales TTM: | 97.8998 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 192 |